Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 4, 2013, Pages 733-745

  Sun, Yuliang ^a   Dey, Nandini ^a,b   Brammer, Melissa ^c   De, Pradip ^a,b   Leyland Jones, Brian ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b UNIVERSITY OF SOUTH DAKOTA   (United States)

^c GENENTECH INC   (United States)

Author keywords

Angiogenesis; Breast cancer; HER2; Trastuzumab resistant; Trastuzumab sensitive; Xenograft

Indexed keywords

BEVACIZUMAB; CD31 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRASTUZUMAB; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOADING DRUG DOSE; MAINTENANCE THERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; MICE, NUDE; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84885384027     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2233-7     Document Type: Article

References (27)

1. Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, Lofgren JA, Tindell C, Evans DP, Maiese K, Scher HI, Sliwkowski MX (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2(2):127-137
2. Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M (2009) Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 69(24):9330-9336. doi: 10.1158/0008-5472.CAN-08-4597
3. Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, Blattler WA, Lambert JM, Chari RV, Lutz RJ, Wong WL, Jacobson FS, Koeppen H, Schwall RH, Kenkare-Mitra SR, Spencer SD, Sliwkowski MX (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68(22):9280-9290. doi: 10.1158/0008-5472.CAN-08-1776
4. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9
5. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM, Group CS (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109-119. doi: 10.1056/NEJMoa1113216
6. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE (2007) Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357(26):2666-2676. doi: 10.1056/NEJMoa072113
7. Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A, Romieu G (2010) Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28(20):3239-3247. doi: 10.1200/JCO.2008.21.6457
8. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL (2008) A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 68(1):206-215. doi: 10.1158/0008-5472.CAN- 07-0669
9. Pradip D, Peng X, Durden DL (2003) Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase. J Biol Chem 278(43):41661-41669. doi: 10.1074/jbc.M306491200
10. Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD, Durden DL (2008) The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 68(6):1862-1871. doi: 10.1158/0008-5472.CAN-07-1182
11. Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK (1989) Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures in vitro. Cell 58(5):933-943. doi: 10.1093/annonc/mdm431
12. Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP (2008) ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 19(1):73-80. doi: 10.1093/annonc/mdm431
13. Chakrabarty A, Rexer BN, Wang SE, Cook RS, Engelman JA, Arteaga CL (2010) H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3. Oncogene 29(37):5193-5203. doi: 10.1038/onc.2010.257
14. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137. doi: 10.1038/35052073
15. Motoyama AB, Hynes NE, Lane HA (2002) The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62(11):3151-3158
16. Drebin JA, Link VC, Greene MI (1988) Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 2(3):273-277
17. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8(6):1720-1730
18. Kasprzyk PG, Song SU, Di Fiore PP, King CR (1992) Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res 52(10):2771-2776
19. Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, Thompson D, Shastry M, Burris HA 3rd, Hainsworth JD (2011) Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer. Clin Breast Cancer 11(5):297-305. doi: 10.1016/j.clbc.2011.04.002
20. Slamon DJ, Gomez HL, Kabbinavar FF, Amit O, Richie M, Pandite L, Goodman V (2008) Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. In: ASCO annual meeting proceedings (post-meeting edition), vol 26, no 15S (May 20 Supplement), 2008, 1016
21. Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64(7):2343-2346
22. Hamel E (2008) An overview of compounds that interact with tubulin and their effects on microtubule assembly. Cancer Drug Discovery and Development: The role of microtubules in cell biology, neurobiology and oncology. Humana press, Totowa, NJ
23. Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4):363-375
24. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28(16):2698-2704. doi: 10.1200/JCO.2009.26.2071
25. Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA (2011) Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 29(4):398-405. doi: 10.1200/JCO.2010.29.5865
26. Perez EA, Dirix LY, Kocsis J, Gianni L et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2 positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomised, multicenter, open-label phase2 study. In: 35th ESMO, Milan, Italy, 8-12 Oct 2010
27. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Dieras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K, Group ES (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367(19):1783-1791. doi: 10.1056/NEJMoa1209124